Opendata, web and dolomites

Vezics

Highly efficient, scalable chromatography platform for high-quality exosome isolation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Vezics" data sheet

The following table provides information about the project.

Coordinator
VIVOSCREEN KUTATASFEJLESZTESI KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: ZARAND KOZ 4/C
city: BUDAPEST
postcode: 1031
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.vezics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIVOSCREEN KUTATASFEJLESZTESI KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) coordinator 50˙000.00

Map

 Project objective

There is enormous interest in using exosomes in the diagnosis and monitoring of cancer and other diseases, as well as their use as therapeutical tools. These cell-derived vesicles that are present in most bodily fluids are increasingly considered the “future of biomedicine”. However, in terms of clinical applications, we are far from realising exosomes’ full potential. The greatest barrier is the lack of dependable protocols for their isolation. Vivoscreen is developing a novel platform for exosome isolation based on size exclusion chromatography (SEC) and immune affinity chromatography (IAC). Capitalising on very promising research results, the Vezics platform intends to offer all the advantages of SEC and IAC, while eliminating its disadvantages with regards to exosome isolation. The Vezics platform utilizes SEC as a first stage for exosome isolation. SEC media are selected according to the properties of the input material. The resulting EV-rich fractions are further purified by (IAC) on columns built for specific scientific needs. As high quality, by-product free isolation of exosomes is a prerequisite for all exosome applications, we expect our development to have a considerable positive impact across the entire spectrum; from research through diagnostic to therapeutic use of exosomes. This is a high risk / high reward project targeting an emerging market segment with extremely high growth potential. This proposal aims a Phase 1 feasibility study to better understand the risks and opportunities involved in this exciting venture. Our proposal was previously submitted to the SME Instrument and received 12.97 points. We hope that in the current proposal we managed to clarify key aspects of our approach to be found worthy for support. Since our last submission, we continued with the development and have built the functional prototype of the Vezics system. Thus, parallel to the feasibility study we can start its experimental validation and refinement as well.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VEZICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VEZICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More